metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant
versus osimertinib
	durvalumab plus osimertinib
	CAURAL (EXPLORATORY), 2019 J Thorac Oncol 2019 May;14(5):933-939. NCT02454933	RCT	mNSCLC - L2 - EGFR mutant	durvalumab plus osimertinib	osimertinib	Patients with EGFR T790M mutation positive locally advanced/metastatic NSCLC (stage IIIB–IV) (previous treatment 1 to >4)	14 / 15	some concern	inconclusive

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

deaths (OS) E

progression or deaths (PFS) E

RFS/DFS E

RCT

mNSCLC - L2 - EGFR mutant

durvalumab plus osimertinib

osimertinib

Patients with EGFR T790M mutation positive locally advanced/metastatic NSCLC (stage IIIB–IV) (previous treatment 1 to >4)

14 / 15